NIH-funded research R21 grant

Targeting a stress-specific function of a DNA replication protein to boost oral cancer therapy

Official title: Targeting the stress-specific function of replication protein A in oral squamous cell carcinoma

Funded at Univ of North Carolina Chapel Hill · NIH-11321521 · Data updated 2026-11-12

A short, targeted NIH grant explores a new way to make existing treatments work better for oral cancer by attacking a special function of a DNA replication protein that cancer cells rely on.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionUniv of North Carolina Chapel Hill
NIH-funded
Lab location1 site (Chapel Hill, United States)
Project startMay 1, 2025
Project endApril 30, 2027
Funding year2026
Award (this year)$192,865
NIH project number5R21DE034524-02
Project IDNIH-11321521 on NIH RePORTER

Who could benefit from this research

Could help

Patients with oral squamous cell carcinoma could be eligible for future studies testing this approach in combination with current therapies.

Less likely to help

Patients whose tumors do not rely on the targeted replication stress mechanism may not benefit.

What this research studies

This project focuses on oral squamous cell carcinoma, a cancer with a substantial global impact. It proposes targeting a specific function of a DNA replication protein to selectively worsen cancer cell stress while trying to minimize harm to normal cells. Researchers will examine how the RPA70N protein motif helps cancer cells cope with replication stress and whether blocking it can enhance standard treatments. The work involves molecular and cellular studies to understand protein interactions and the resulting effects on cancer cell survival. If successful, this approach could inform more effective combination therapies for OSCC.

Why it matters

Potential benefit: If successful, the approach could improve how OSCC responds to treatment and potentially reduce tumor growth or recurrence.

How similar studies have gone: Previous work in similar replication-stress targeting concepts has shown promise in preclinical models, though direct application to OSCC is still early stage.

Where this research is happening

  • Univ of North Carolina Chapel Hill
    Chapel Hill, United States
    Active

Researchers

  • Principal investigator: Peng, Aimin — Univ of North Carolina Chapel Hill
  • Study coordinator: Peng, Aimin

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.